Home » Agenda » Day 1

Day 1

Protein & Antibody World Congress 2023 Europe

London, United Kingdom

Day 1 - Monday 13th November 2023

  • Potential applications on cellular pathway alteration at the protein level: targeted protein sequestration, protein recruitment, protein degradation, and selective
    inhibition of binding interfaces
  • Biochemical, genetic, and technological challenges in genetic code engineering


  • Recent advances in computational/AI-based techniques for antibody engineering and discovery
  • AI methods relevant for antibody development
  • Computational antibody design procedures with emphasis to machine learning
  • Examining the current biological and engineering challenges facing the biomanufacturing of antibodies
  • Emerging technologies to reduce biomanufacturing challenges.
  • Innovations in process analytical technologies and single use technologies to improve current performance of mAb production processes.
  • Docking setup using the wrapper code approach to optimize the DOCK program for large-scale computation as well as docking analysis using variance and promiscuity
  • Relevance of Small angle X-ray scattering (SAXS) for quantifying conformational flexibility in proteins
  • Feasibility of MARS for the measurement of both protein purity-related and formulation-related PQAs
  • Potential to be a powerful methodology to improve the efficiency of biopharmaceutical development and manufacturing


  • Comprehensive overview of validated, forgotten and newly develop payloads with diverse procedures of action.
  • Key role of Payload Diversification in the field of future ADC development
  • Advantages of payloads and benefits of payload diversification
  • Evolution of Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) targets for cancer therapy
  • Use of scTRAIL and associated peptide linkers as promising strategy for antitumor therapeutics
  • Steps in the process of antibody discovery and development
  • Differences in developability analyses in discovery and development stages
  • Developability-related considerations and assessment at the discovery stage
  • Analysis and optimization of developability-related attributes
  • Carbohydrates as promising targets for vaccine development against infectious disease
  • Strategies on overcoming challenges carbohydrate-based vaccine design and development approaches targeting cancer and other diseases
  • How can general protein language models efficiently evolve human antibodies?
  • Could these models be applicable to evolving more unnatural, de novo designed proteins
  • Comparison to other sequence-based methods
  • Computational efficiency of this approach
  • Leveraging data beyond protein sequence information including protein structure information and binding affinity data to further improve the outcome
Scroll to Top